Gastroenterology

Individuals who sought outpatient mental health and addiction services were generally younger, proportionately more female, more likely to have a psychiatric comorbidity, and more likely to have had their index alcohol-related hospitalization attributed to than to other diagnoses such as harmful alcohol use or alcoholic liver disease.

Hepatology experts discuss educating patients with hepatic encephalopathy on managing medications and supplements.

Kimberly A. Brown, MD, shares approaches to educating patients on management of hepatic encephalopathy and the importance of medication adherence and nutrition.

There was an association between NAFLD in the South-Asian population and diabetes mellitus, hypertension, dyslipidemia, general obesity, central obesity and metabolic syndrome.

Drs Arun Jesudian and James William discuss approaches for proper discharge planning and transition of care and how this can reduce readmission for patients with hepatic encephalopathy.

A transplant hepatologist shares advice for emergency department physicians and clinicians to improve the diagnosis and treatment of hepatic encephalopathy.

The median exposure of vedolizumab was 1.93 years and lower incidence rates were found for infliximab or adalimumab.

The prevalence rate was the highest in methadone clinics followed by correctional institutions, HIV clinics, and the surveillance program.

A new analysis found differences in the gut bacteria seen in adults with obesity, suggesting that changes in the gut microbiota that predispose to adult obesity may begin in early childhood.

RBX2660 showed similar efficacy and safety in treating patients with and without immunocompromised conditions.

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

There is no additional risk of developing new cancers for patients treated with IBD medications.

For the maintenance trial, 42% and 55% of patients treated with upadacitinib 15 mg and 30 mg achieved clinical remission at week 52, compared to 14% of the placebo group.

Expert hepatologists comment on primary care providers using rifaximin to manage and prevent episodes of hepatic encephalopathy.

Arun B. Jesudian, MD, and Kimberly A. Brown, MD, highlight clinical trial data of rifaximin for the treatment of hepatic encephalopathy.

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

A redo surgery often improves the quality of life in a number of ways for patients with ulcerative colitis.

James Williams, MS, DO, FACEP, provides insight on the importance of medication reconciliation when managing patients with hepatic encephalopathy.

Arun Jesudian, MD, and James Williams, MS, DO, FACEP, highlight precipitating factors for HE and medication compliance for the condition.

Pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery compared to the cohort without celiac disease.

There was a reduction in medical costs that offset the increased pharmacy costs in the patients who were treated with rifaximin.

In 2022, dupilumab became the first treatment approved by the US Food and Drug Administration for the treatment of patients with EoE.

In the induction trial, guselkumab resulted in a higher rate of clinical remission, as well as symptomatic remission, clinical response, endoscopic improvement, and histo-endoscopic mucosal improvement at week 12.

The linaclotide group had significant improvements from baseline in the 12 week SBM frequency rate and 12-week stool consistency.

Kimberly A. Brown, MD, reviews the use of lactulose and rifaximin as first-line treatment of hepatic encephalopathy.